Founded in 1973, Abingworth has over $1 billion under management and invests in all life sciences sectors and stages of development, from start-ups to publicly traded companies. With 142 life science companies invested in, Abingworth has completed 60 IPOs and 40 mergers and acquisitions. The firm has a team of 27 professionals across offices in London, Menlo Park, and Boston, and focuses on healthcare, information technology, life science, and technology-based sectors in the United States and Europe. Abingworth became part of Carlyle in August 2022.